Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Poll|June 3, 2022
The Role of Psychedelics in Psychiatry: Helpful or Hoax?
Author(s)Psychiatric Times Editors
What are your thoughts on psychedelics?
Advertisement
Some say we are undergoing a
Do you think psychedelics can play a productive role in addressing psychiatric disorders?
Would you recommend psychedelics to your patients?
Have you referred your patients for psychedelic treatment/have any one of your patients received psychedelic-assisted therapy?
We want to know more about your thoughts and experiences with psychedelics and clinical practice! Write to us at
Advertisement
Related to this article
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
3
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
4
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
5